Inventor · disambiguated record
Matthew S. Mccammant
Also filed as: MCCAMMANT MATTHEW · MCCAMMANT MATTHEW S
5 granted patents·7 pending applications·10 citations·filing 2019–2025
70Inventor score
Files withINCYTE CORP12
Top patents by PatentIndex Score
12 records- 0191US11897891B2Tricyclic heterocycles as FGFR inhibitorsINCYTE CORP·Filed 2020·Granted Feb 13, 2024·5 cites·41 claims
- 0288US11168089B2Fused pyrimidine derivatives as A2A / A2B inhibitorsINCYTE CORP·Filed 2019·Granted Nov 9, 2021·5 cites·36 claims
- 0380US11939328B2Quinoline compounds as inhibitors of KRASINCYTE CORP·Filed 2022·Granted Mar 26, 2024·0 cites·35 claims
- 0479US12378243B2Quinoline compounds as inhibitors of KRASINCYTE CORP·Filed 2024·Granted Aug 5, 2025·0 cites·34 claims
- 0575US2025313567A1Imidazopyrimidines and triazolopyrimidines as a2a / a2b inhibitorsINCYTE CORP·Filed 2025·Application pending·0 cites
- 0674US2025368641A1Quinoline compounds as inhibitors of krasINCYTE CORP·Filed 2025·Application pending·0 cites
- 0764US2024368156A12-azabicyclo[2.2.1]heptane kras inhibitorsINCYTE CORP·Filed 2024·Application pending·0 cites
- 0862US2024358702A1Cyclic urea kras inhibitorsINCYTE CORP·Filed 2024·Application pending·0 cites
- 0960US11873304B2Fused pyrimidine derivatives as A2A/A2B inhibitorsINCYTE CORP·Filed 2021·Granted Jan 16, 2024·0 cites·44 claims
- 1060US2024390340A1Pyrrolidine kras inhibitorsINCYTE CORP·Filed 2024·Application pending·0 cites
- 1160US2019292188A1Imidazopyrimidines and triazolopyrimidines as a2a / a2b inhibitorsINCYTE CORP·Filed 2019·Application pending·0 cites
- 1257US2023226040A1Combination therapy comprising an fgfr inhibitor and a kras inhibitorINCYTE CORP·Filed 2022·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Matthew S. Mccammant files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →